Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion type Assertion NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_head.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion description "[High-level amplification of EIF3S3 was found in 11 of 125 (9%) of pT1/pT2 tumors, 12 of 44 (27%) of pT3/pT4 tumors, and 8 of 37 (22%) of lymph node metastases as well as in 26 of 78 (33%) and 15 of 30 (50%) of hormone refractory locally recurrent tumors and metastases, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_provenance.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion evidence source_evidence_literature NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_provenance.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion SIO_000772 11733359 NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_provenance.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion wasDerivedFrom befree-20140225 NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_provenance.
- NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_assertion wasGeneratedBy ECO_0000203 NP817175.RAsTP5vaVZpUxs38FhRuLD_R4P9DtvFVkcONcP0TGH7eE130_provenance.